The Board of Directors has elected Dr. Manisha Shah as the incoming chair of ITOG. Her three-year term as the Director of ITOG will begin following the 2018 Annual Meeting in Los Angeles. Dr. Shah currently serves as ITOG Secretary, Co-chair of the Protocol Committee and has been on the Executive Committee for three years.
Dr. Shah is the co-Director of the Neuroendocrine Tumor Program and Professor of Internal Medicine in the Division of Medical Oncology at The Ohio State University, Comprehensive Cancer Center. Dr. Shah's research focuses on the discovery of new targeted therapies for patients with thyroid cancers, neuroendocrine cancers, and adrenal cancers. She has served as the principle investigator of numerous clinical trials for the treatment of progressive thyroid cancer. She was instrumental in the early studies examining the efficacy of sorafenib in the treatment of differentiated thyroid cancer, the first trial of its kind in this patient population. The findings of this study, on which she served as a lead PI, resulted in the acceptance of sorafenib as a first-line therapy and approval by the FDA for patients with iodine-refractory thyroid cancer. Dr. Shah also served as the lead investigator for ITOG's first clinical trial, the results of which were recently published in the prestigious Journal of Clinical Oncology.
She continues to strive to improve our understanding of thyroid cancer through these and other clinical trials. The studies shed light on the mechanisms of tumor progression, the appropriate treatment of aggressive tumors, and how tumor genomics impact response to therapy. She will utilize these insights and her boundless energy to propel ITOG forward in continuing effort to create novel clinical trials for the management of progressive thyroid cancer.